Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma.
OBJECTIVE
Response rates of cutaneous-subcutaneous or lymph node metastases of melanoma to systemic chemotherapy are rather low. We report our clinical experience with superficial and deep regional hyperthermia in combination with radiotherapy and/or chemotherapy with carboplatin.


METHODS
We treated 15 patients with metastatic melanoma (6 men, 9 women; age 39-84 years, mean age 60 years) by using superficial or deep regional hyperthermia produced by electromagnetic energy. Superficial hyperthermia was delivered to skin or lymph node metastases in combination with radiochemotherapy in 12 patients, while deep regional hyperthermia was administered with an annular array applicator to lymph node metastases either in combination with radiochemotherapy (1 patient) or with carboplatin alone (2 patients). The clinical response was assessed by clinical evaluation and/or computer tomography and/or ultrasonography at monthly intervals.


RESULTS
Both superficial and deep regional hyperthermia was well tolerated. We observed 5 complete local remissions (34%), 6 partial local remissions (40%) and 2 patients with stable disease (13%). The best results were obtained in cutaneous or retroperitoneal metastases.


CONCLUSIONS
Local response can be achieved in inoperable metastatic melanoma using superficial or deep regional hyperthermia in combination with radiochemotherapy or chemotherapy.
Richtig
E
E
Department of Dermatology, University of Graz, Auenbruggerplatz 8, 8036 Graz, Austria. erika.richtig@uni-graz.at
Hoff
M
M
Rehak
P
P
Kapp
K
K
Hofmann-Wellenhof
R
R
Zalaudek
I
I
Poschauko
J
J
Uggowitzer
M
M
Kohek
P
P
Smolle
J
J
D000368:Aged; D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D012186:Retroperitoneal Neoplasms / Q000473:pathology / Q000556:secondary / Q000628:therapy; D012878:Skin Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D016896:Treatment Outcome